B
BDgene Technology
A gene therapy innovative drug developer
About BDgene Technology
BDgene Therapeutics is a leading high-tech biopharmaceutical company in China, specializing in the development of gene therapy solutions for major diseases that were previously considered incurable. The company operates in the biopharmaceutical market, focusing on advanced gene editing and delivery technologies. BDgene's core clients include top-tier tertiary hospitals, international pharmaceutical companies, and research institutions. The business model revolves around the development and commercialization of gene therapy treatments, leveraging proprietary technologies such as the BDlenti Platform for lentiviral vector delivery and viroid mRNA VLP for gene editing. Revenue is generated through partnerships, licensing agreements, and clinical applications of their therapies. The company's advisory team comprises authoritative experts in gene therapy, clinicians, and executives from listed pharmaceutical companies, ensuring a robust and innovative approach to drug development.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2018
- Headquarters
- Huangpu, China
- Employees
- 1
- Open positions
- None listed
- Dealroom signal
- 56.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Apr 2026 | $28M | $110M | Gongshu Guotou Investment · Hongcheng Investment · Efung Capital | ↗ |
| SERIES BOther financing | Jun 2023 | $28M | $110M | National Small and Medium Enterprise Development · Hermed Capital · Sunland fund · Penglai Capital | ↗ |
Growth signals
Latest recorded traffic for BDgene Technology is 2.3K monthly website visits, up 130% over the last three months. BDgene Technology's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
National Small and Medium Enterprise Development- HCHermed Capital
Sunland fund- PCPenglai Capital
- CCChunhe Capital
Series B and later3 investors entered at this stage
- GIGongshu Guotou Investment
- HIHongcheng Investment
- ECEfung Capital
Other known investors1 additional known investor
Shanghai Jiao Tong University
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about BDgene Technology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See BDgene Technology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.